Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

Stay well-informed and make prudent decisions using our Ratings Table. Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug ...

Compr Ophthalmol Update. 2007;8(1):39-49. Disclosure: Dr. Balcer has served as a consultant for development of visual outcomes for trials for Biogen Idec, Merck Serono, Sirtris Pharmaceuticals ...

Jeanne Whalen writes about the U.S. economy from the Chicago bureau. She previously covered healthcare, general news and ...

Earlier this year UCB signed a major licensing deal with Biogen Idec to market all of the US company's brands in Asia's emerging markets, including China, by far the most lucrative. "Who is the ...

John Kell wrote about general corporate news and major market movers.

Biogen Idec's STX-100 and FibroGen's FG-3019. The active ingredient in Ofev is also approved at a higher dose in a lung cancer therapy - called Vargatef - which was recommended for NHS use by NICE ...

The table is limited by our hospital pharmacy's formulary; however, our purpose was to update the current literature. The table is intended for use as a guide when medications labeled for ...

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why ...

Biogen Netherlands has received marketing authorisation from the UK MHRA for its Skyclarys to treat Friedreich's ataxia.